Anika Therapeutics (ANIK) Tops Q4 EPS by 21c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
Sidoti Downgrades Anika Therapeutics (ANIK) to Neutral
February 22, 2019 8:48 AM ESTSidoti analyst James Sidoti downgraded Anika Therapeutics (NASDAQ: ANIK) from Buy to Neutral with a price target of $41.00 (from $56.00).
The analyst cited uncertainty regarding CINGAL approval.
For an analyst ratings summary and ratings history on Anika Therapeutics... More
